<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000788</url>
  </required_header>
  <id_info>
    <org_study_id>CPCRA 030</org_study_id>
    <secondary_id>11580</secondary_id>
    <nct_id>NCT00000788</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone</brief_title>
  <official_title>A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics and safety of concomitant administration of methadone and&#xD;
      fluconazole.&#xD;
&#xD;
      Injection drug users constitute the second largest subset of the U.S. population at risk for&#xD;
      HIV infection and AIDS-associated mortality. Narcotic addiction is often treated by use of&#xD;
      methadone. Fluconazole has been shown to be highly effective in treating symptomatic mucosal&#xD;
      candidiasis, but it is unknown whether fluconazole affects methadone metabolism, which could&#xD;
      result in symptoms of methadone withdrawal or overdose in patients taking the drugs in&#xD;
      combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Injection drug users constitute the second largest subset of the U.S. population at risk for&#xD;
      HIV infection and AIDS-associated mortality. Narcotic addiction is often treated by use of&#xD;
      methadone. Fluconazole has been shown to be highly effective in treating symptomatic mucosal&#xD;
      candidiasis, but it is unknown whether fluconazole affects methadone metabolism, which could&#xD;
      result in symptoms of methadone withdrawal or overdose in patients taking the drugs in&#xD;
      combination.&#xD;
&#xD;
      Patients are randomized to receive methadone plus either fluconazole or placebo in clinic&#xD;
      daily for 16 days. Study drugs are administered as close to 8 AM as possible. Patients must&#xD;
      visit the Fort Greene clinic on study days 1, 2, 15, and 16; they may receive treatment at&#xD;
      their home clinics on days 3 through 14.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">June 1994</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Candidiasis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral therapy.&#xD;
&#xD;
          -  Intermittent acetaminophen, aspirin, and ibuprofen.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  CD4 count &gt;= 250 cells/mm3 within 3 months prior to study entry.&#xD;
&#xD;
          -  Received a stable dose of methadone for a minimum of 30 days prior to study entry.&#xD;
&#xD;
          -  Negative urine toxicology screen (except for methadone or methadone metabolites)&#xD;
             within 14 days prior to study entry.&#xD;
&#xD;
          -  Reasonably good health.&#xD;
&#xD;
          -  Life expectancy of at least 6 months.&#xD;
&#xD;
          -  Ability and willingness to comply with protocol requirements.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Patients will be recruited from the methadone maintenance treatment program currently&#xD;
             administered by Addiction Research and Treatment Corporation. Enrollment of women is&#xD;
             encouraged.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Patients who are currently enrolled in CPCRA treatment and prophylaxis trials are&#xD;
             eligible for this study provided they have been permanently removed from study drug on&#xD;
             the other protocol.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Stable dose of methadone for a minimum of 30 days prior to study entry.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior antiretroviral therapy (dose should be stable for 14 days prior to study entry).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Known sensitivity to azoles, methadone, and other opiate narcotics.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Amiodarone.&#xD;
&#xD;
          -  Anesthetics, general.&#xD;
&#xD;
          -  Barbiturates.&#xD;
&#xD;
          -  Carbamazepine.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Ciprofloxacin.&#xD;
&#xD;
          -  Dexamethasone.&#xD;
&#xD;
          -  Disulfiram.&#xD;
&#xD;
          -  Erythromycin.&#xD;
&#xD;
          -  Fluoroquinolones.&#xD;
&#xD;
          -  Fluoxetine.&#xD;
&#xD;
          -  Gestodene.&#xD;
&#xD;
          -  Hydrochlorothiazide.&#xD;
&#xD;
          -  Hypoglycemics, oral.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Itraconazole.&#xD;
&#xD;
          -  Ketoconazole.&#xD;
&#xD;
          -  Levomepromazine.&#xD;
&#xD;
          -  MAO inhibitors.&#xD;
&#xD;
          -  Methoxsalen.&#xD;
&#xD;
          -  Nafcillin.&#xD;
&#xD;
          -  Narcotic analgesics.&#xD;
&#xD;
          -  Naringenin.&#xD;
&#xD;
          -  Norethindrone.&#xD;
&#xD;
          -  Omeprazole.&#xD;
&#xD;
          -  Pentazocine.&#xD;
&#xD;
          -  Phenothiazines.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Quinidine.&#xD;
&#xD;
          -  Ranitidine.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Sedative hypnotics.&#xD;
&#xD;
          -  Sulfaphenazole.&#xD;
&#xD;
          -  Tranquilizers.&#xD;
&#xD;
          -  Tricyclic antidepressants.&#xD;
&#xD;
          -  Troleandomycin.&#xD;
&#xD;
          -  Warfarin.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 30 days prior to study entry:&#xD;
&#xD;
          -  Ketoconazole, fluconazole, or itraconazole.&#xD;
&#xD;
          -  Experimental drugs.&#xD;
&#xD;
        Alcohol or illicit drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cobb M</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Letts A</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Addiction Research and Treatment Corp</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther. 1998 Jun;63(6):655-62. doi: 10.1016/S0009-9236(98)90089-3.</citation>
    <PMID>9663180</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methadone</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

